Pulmonx Reports First Quarter 2026 Financial Results
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. Recent Highlights Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basisDelivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decreaseDelivered $7.3 million in international revenue in the first quarter of 2026, representing a 12% year-over-year decrease and a decrease of 21% on a constant currency basis; excluding China, year-over-year international revenue increased 22% and 9% on a constant currency basisRealized gross margin of 78% in the first quarter of 2026As previously reported, refinanced prior debt under a new 5-year interest-only credit
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- Pulmonx (LUNG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Pulmonx reiterates $90M-$92M 2026 revenue guidance amid cost cuts and expects return to growth in 2H 2026 [Seeking Alpha]Seeking Alpha
- Pulmonx Q1 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Pulmonx Reports First Quarter 2026 Financial Results [Yahoo! Finance]Yahoo! Finance
LUNG
Earnings
- 4/29/26 - In-Line
LUNG
Analyst Actions
- 3/5/26 - Canaccord Genuity
LUNG
Sec Filings
- 4/29/26 - Form 8-K
- 4/22/26 - Form ARS
- 4/22/26 - Form DEF
- LUNG's page on the SEC website